Greenwich LifeSciences, Inc. - Common stock (GLSI)
25.20
+2.90 (13.00%)
NASDAQ · Last Trade: Jan 22nd, 3:02 PM EST
Detailed Quote
Previous Close
22.30
Open
27.19
Bid
25.10
Ask
25.20
Day's Range
22.52 - 29.90
52 Week Range
7.780 - 32.91
Volume
4,617,705
Market Cap
349.13M
PE Ratio (TTM)
-17.26
EPS (TTM)
-1.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
771,576
Chart
About Greenwich LifeSciences, Inc. - Common stock (GLSI)
Greenwich Lifesciences Inc is a biotechnology firm focused on advancing innovative therapies for cancer treatment, particularly in the realm of immunotherapy. The company is dedicated to developing its novel drug candidates to harness the body's immune system in targeting and destroying cancer cells. Through rigorous research and clinical trials, Greenwich Lifesciences aims to provide effective treatment options for patients, with a specific emphasis on improving outcomes and quality of life for those affected by various types of cancer. The firm's commitment to scientific excellence and patient-centric approaches positions it at the forefront of cancer therapeutics. Read More
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first commercially manufactured GP2 lot for the FLAMINGO-01 Phase III clinical trial.
The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
ORLANDO, FLORIDA / ACCESS Newswire / June 27, 2025 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc. (Nasdaq:GLSI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, June 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning the Company and its directors’ and officers’ possible violations of state laws.
Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following year end update.
